3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia
7
Lymphoma, Non-Hodgkin
6
Burkitt Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Lymphoma
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Acute
4
Blast Crisis
4
Waldenstrom Macroglobulinemia
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Accelerated Phase
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hematologic Neoplasms
3
Dendritic Cell Sarcoma, Interdigitating
3
Congenital Abnormalities
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Methylprednisolone Hemisuccinate
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled